STM2457经YTHDF1/EIF3C抑制Huh-7肝癌细胞增殖-华夏医学-CSCIED科技核心评价数据库-手机版

STM2457经YTHDF1/EIF3C抑制Huh-7肝癌细胞增殖

STM2457 inhibits the proliferation of Huh?7 liver cancer cell sthrough YTHDF1/EIF3C

ES评分 0 浏览量：20 下载量：0

DOI	10.19296/j.cnki.1008-2409.2025-01-004
刊名	华夏医学 ACTA MEDICINAE SINICA
年，卷(期)	2025, 38(01)
作者	庄家敏1赵培培1,2杨媛媛1,2周雨佳1刘栩3SREANG Lyly4涂剑1,
作者单位	1中国广西桂林；2中国广西桂林；3中国广西桂林；4中国广西桂林
摘要	论文探究甲基转移酶3（METTL3）抑制剂STM2457对Huh-7人肝癌细胞增殖能力的作用及其机制。结果表明，相较于癌旁组织，肝癌组织中增殖标志物PCNA表达显著增强的同时，METTL3、YTHDF1、EIF3C的表达也显著增强；STM2457可显著抑制Huh-7细胞的增殖能力（P<0.01）,靶向抑制METTL3表达的同时，还可下调YTHDF1、EIF3C、PCNA的表达；METTL3 siRNA下调METTL3表达的同时，还可同步下调YTHDF1、EIF3C、PCNA的表达。
Abstract	The study investigated the effects of the methyltransferase 3 (METTL3) inhibitor STM2457 on the proliferation ability of Huh?7 human hepatocellular carcinoma cells and its underlying mechanisms. The results showed that compared to adjacent non?tumor tissues, the expression of the proliferation marker PCNA was significantly enhanced in hepatocellular carcinoma tissues, accompanied by significantly increased expression of METTL3, YTHDF1, and EIF3C. STM2457 significantly inhibited the proliferation ability of Huh?7 cells (P?
关键词	STM2457;甲基转移酶3;YTH N6-甲基腺苷RNA结合蛋白1;真核起始因子3;肝癌增殖;
KeyWord	STM2457;methyltransferase 3;YTH N -methyladenosine RNA-binding protein 1 ;eukaryotic initiation factor 3;proliferation of liver cancer
基金项目
页码	22-27

参考文献
相关文献

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
[J]. CA Cancer J Clin, 2024, 74(3):229-263.

[2] 刘叶琴，周志刚，杨明辉，等.FOX家族促进肝纤维化的研究进展
[J].华夏医学，2023,36(6):170-174.

[3] ANWANWAN D, SINGH S K, SINGH S, et al. Challenges in liver cancer and possible treatment approaches
[J]. Biochim Biophys Acta Rev Cancer, 2020,1873 (1):188314.

[4] ZHANG N, ZUO Y X, PENG Y, et al. Function of N6 Methyladenosine Modification in Tumors
[J]. J Oncol, 2021,2021:6461552.

[5] ZHAO J D, LI G Y, LU X Y, et al. Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications
[J]. Front Pharmacol, 2024,15:1376005.

[6] JIN Q, QU H N, QUAN C S. New insights into the regulation of METTL3 and its role in tumors
[J]. Cell commun Signal，2023，21（1）：334．

[7] WU X J, ZENG M, WEI Y Y, et al. METTL3 and METTL14?mediated N6?methyladenosine modification of SREBF2?AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2
[J]. Sci Rep，2024，14（1）：6155．

[8] YANG Z, WANG T F, WU D J, et al. RNA N6?methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer
[J]. J Exp Clin Cancer Res，2020，39（1）：203．

[9] CHEN H F, YAO J M, BAO R J, et al. Cross?talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer
[J]. Mol Cancer，2021，20（1）：29．

[10] HUANG L T, ZHU J, KONG W K X, et al. Expression and prognostic characteristics of m6A RNA methylation regulators in colon cancer
[J]. Int J Mol Sci，2021，22（4）：2134．

[11] LIU T, WEI Q L, JIN J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation
[J]. Nucleic Acids Res，2020，48（7）：3816-3831．

[12] YANKOVA E, BLACKABY W, ALBERTELLA M, et al. Small?molecule inhibition of METTL3 as a strategy against myeloid leukaemia
[J]. Nature，2021，593（7860）：597-601．

[13] 高毅男，王培君，逯素梅，等．甲基转移酶样3抑制剂 STM2457通过调节线粒体功能改善代谢相关脂肪性肝病［J］．南方医科大学学报，２０２３，４３（１０）：１６８９－１６９６．

[14] HUNG J H, TENG C F, HUNG H C, et al. Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies
[J]. Ann Hepatol，2024，29（6）：101546．

[15] YIN Y, FENG W B, CHEN J, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
[J]. Exp Hematol Oncol，2024，13（1）：72．

[16] QU Y, GAO N N, ZHANG S W, et al. Role of N6?methyladenosine RNA modification in cancer
[J]. Med comm（2020），2024，5（9）：e715．

[17] MA S, LI J H, SHEN C H, et al. The m6A?related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma
[J]. Front Immunol，2023，14：1227593．

[18] 夏坤，陈向恒，欧阳辉，等．YTHDF1在肿瘤中的研究进展［J］．华夏医学，２０２３，３６（３）：１７７－１８２．

[19] WANG Q Q, GUO X C, LI L, et al. N6?methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification
[J]. Cell Death Dis，2020，11（10）：911．

[20] YANG R, YANG C, SU D J, et al. METTL3?mediated RanGAP1 promotes colorectal cancer progression through the MAPK pathway by recruiting YTHDF1
[J]. Cancer Gene Ther，2024，31（4）：562-573．

[21] WANG S W, ZHANG W Y, WANG Z J, et al. METTL3?m6A?YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction?associated steatotic liver disease
[J]. Cell Signal，2024，121：111303．

[22] HU J Y, YANG L, PENG X Q, et al. METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma
[J]. Hum Cell，2022，35（6）：1838-1855．

[23] ZHANG R, CHEN P, WANG Y B, et al. Targeting METTL3 enhances the chemosensitivity of non?small cell lung cancer cells by decreasing ABCC2 expression in an m6A?YTHDF1?dependent manner
[J]. Int J Biol Sci，2024，20（12）：4750-4766．

[24] GAO J, FANG Y, CHEN J F, et al. Methyltransferase?like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy
[J]. Oncogene，2023，42（33）：2507-2520．

[25] WANG L N, YANG Q X, ZHOU Q Y, et al. METTL3?m6A?EGFR?axis drives lenvatinib resistance in hepatocellular carcinoma
[J]. Cancer Lett，2023，559：216122．

引用本文

庄家敏赵培培,杨媛媛,周雨佳刘栩SREANG Lyly涂剑. STM2457经YTHDF1/EIF3C抑制Huh-7肝癌细胞增殖 [J]. 华夏医学. 2025; 38; (01). 22 - 27.

文献评论

相关学者

相关机构